Cost-Effectiveness of Rapid Susceptibility Testing for Second Line Drugs against Tuberculosis.

Dowdy DW, van’t Hoog AH, Shah M, Cobelens FGJ.

Int J Tuberc Lung Dis 2014;18(6):647-54.

Abstract  http://www.ncbi.nlm.nih.gov/pubmed/?term=Cost-Effectiveness+of+Rapid+Susceptibility+Testing+for+Second+Line+Drugs+against+Tuberculosis

KNCV has been fighting TB since its establishment in 1903. Over the past 120 years, the organization has acquired indispensable knowledge and experience in the field of effective TB prevention and care, resulting in pre-elimination in the Netherlands and significant contributions to global evidence generation, policy development and TB program implementation worldwide.

Our experts
KNCV governance framework and integrity
Our patroness
Partner with us